EVLO (Evelo Biosciences) Total Stockholders Equity: $-26.71 Mil (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Evelo Biosciences Total Stockholders Equity?

Evelo Biosciences EVLO -99.00% Total Stockholders Equity is $-26.71 Mil as of Sep. 2023.

Evelo Biosciences's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-26.71 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Evelo Biosciences's Book Value per Share for the quarter that ended in Sep. 2023 was $-1.42. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Evelo Biosciences's Debt-to-Equity for the quarter that ended in Sep. 2023 was -1.27.

Evelo Biosciences  (OTCPK:EVLO) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Evelo Biosciences's Book Value per Share for the quarter that ended in Sep. 2023 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-26.707-0)/18.854
=-1.42

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Evelo Biosciences's Debt-to-Equity for the quarter that ended in Sep. 2023 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(33.948 + 0) / -26.707
=-1.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evelo Biosciences Total Stockholders Equity Related Terms

Evelo Biosciences Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Evelo Biosciences's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evelo Biosciences Total Stockholders Equity Chart

Evelo Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Stockholders Equity
Get a 7-Day Free Trial 136.95 60.20 30.49 8.67 -4.99

Evelo Biosciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.33 -4.99 -27.39 -46.13 -26.71
What does a Total Stockholders Equity of $-26.71 Mil mean?
Evelo Biosciences (EVLO) has a Total Stockholders Equity of $-26.71 Mil as of Sep. 2023. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Evelo Biosciences and its competitors.
Is Evelo Biosciences' Total Stockholders Equity too high?
Evelo Biosciences' current Total Stockholders Equity is $-26.71 Mil.
How does Evelo Biosciences' Total Stockholders Equity compare to IMNN and EDSA?
Evelo Biosciences' Total Stockholders Equity of $-26.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Evelo Biosciences and its competitors. Evelo Biosciences's current Total Stockholders Equity is $-26.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evelo Biosciences stock overvalued right now?
Evelo Biosciences (EVLO) has a current Total Stockholders Equity of $-26.71 Mil. The current Total Stockholders Equity is $-26.71 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Evelo Biosciences (EVLO), the current Total Stockholders Equity is $-26.71 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evelo Biosciences Business Description

Address 620 Memorial Drive, Cambridge, MA, USA, 02139
Evelo Biosciences Inc is a clinical-stage biotechnology company focused on discovering and developing a new class of oral medicines that act on immune cells in the small intestine with systemic effects. The company is developing EDP1815 as a treatment in psoriasis and atopic dermatitis and EDP2939 in psoriasis.